

# **Palmitoylethanolamide: A Comprehensive Thesis on its Biological Mechanisms and Therapeutic Applications in Sensory and Respiratory Systems**

## **Chapter 1: Introduction to Palmitoylethanolamide (PEA)**

### **1.1. Historical Context, Chemical Profile, and Endogenous Significance**

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide belonging to the N-acylethanolamine (NAE) class of signaling molecules.<sup>1</sup> Its discovery dates back to 1957 when it was first isolated from sources such as soybean lecithin, egg yolk, and peanut meal, with initial reports highlighting its anti-inflammatory properties.<sup>2</sup> Subsequent research confirmed its presence in mammalian tissues, establishing PEA as an endogenous compound.<sup>3</sup> Chemically, PEA is N-(2-hydroxyethyl)-palmitamide, a derivative of the saturated fatty acid palmitic acid and ethanolamine.<sup>1</sup>

A crucial aspect of PEA's biology is its endogenous production. It is synthesized on cellular demand within the lipid bilayer of cell membranes and is found in nearly all tissues of the human body.<sup>1</sup> Unlike many signaling molecules, PEA is not stored; instead, it is produced primarily as part of the body's innate protective mechanism in response to cellular injury or specific disease conditions.<sup>1</sup> This "on-demand" synthesis underscores a dynamic homeostatic role for PEA. The fact that PEA is "produced on demand by almost all the cells in the body"<sup>1</sup> and "largely as part of the body's protective mechanism against any cellular injury or in response to certain disease conditions"<sup>1</sup> suggests that its physiological function is not static but highly responsive to cellular stress and injury. This positions PEA as a key modulator in maintaining local tissue equilibrium, augmenting natural protective responses rather than acting as a systemic, constitutively active molecule.

While PEA is produced endogenously, it is also found in various dietary sources, including egg yolks, peanuts, soybeans, palm oil, and other common foods.<sup>2</sup> However, it is important to note that many commercially available PEA supplements are synthetically produced.<sup>6</sup>

## **1.2. PEA: An Endogenous Modulator and Autacoid Local Injury Antagonist (ALIAmide)**

PEA is recognized as an "autacoid local injury antagonist" (ALIAmide), a term and concept significantly advanced by the work of Nobel laureate Rita Levi-Montalcini.<sup>2</sup> An autacoid is a locally acting substance, and the ALIAmide designation implies that PEA is synthesized locally in response to tissue injury or inflammation and acts to counteract such pathological events at their site of origin.<sup>7</sup> This localized action is pivotal to understanding its physiological role. The levels of PEA in tissues have been observed to fluctuate in response to cell damage, inflammation, and pain across various species, further supporting its role as a responsive local modulator.<sup>4</sup>

The ALIAmide concept, emphasizing local action driven by on-demand synthesis<sup>1</sup>, suggests that exogenous PEA supplementation might preferentially augment the body's natural responses in damaged or inflamed tissues. This targeted action could contribute to its generally favorable side-effect profile observed in numerous studies<sup>3</sup>, as healthy tissues with low PEA turnover might be less affected by systemic administration compared to traditional systemic anti-inflammatory drugs that exert broader, less targeted effects.

PEA performs a wide array of biological functions, most notably exhibiting anti-inflammatory, analgesic, and neuroprotective properties, which have been demonstrated in various experimental models and clinical settings.<sup>1</sup>

## **1.3. Thesis Objectives and Scope**

This thesis aims to provide a comprehensive academic review of Palmitoylethanolamide, with a particular focus on its effects on sensory systems—specifically eyesight, hearing, and olfactory function—and its impact on

respiratory inflammation, including conditions such as influenza and COVID-19. A key objective is to analyze the efficacy and mechanisms of specific PEA formulations, notably ultramicrosized PEA co-formulated with luteolin (umPEALUT) and PEA in combination with alpha-lipoic acid (ALA). Furthermore, this work will delve into the fundamental biological mechanisms through which PEA exerts its effects. Finally, all findings will be synthesized to critically compare the strength of scientific evidence supporting its diverse therapeutic applications.

The structure of this thesis will begin with an exploration of PEA's fundamental biological mechanisms, followed by an analysis of its pharmaceutical formulations and pharmacokinetics. Subsequent chapters will systematically examine the role of PEA in ocular health, auditory disorders, olfactory function, and respiratory inflammation. The thesis will culminate in a comprehensive synthesis and comparative evidentiary analysis, followed by conclusions and future perspectives.

## **Chapter 2: Fundamental Biological Mechanisms of Palmitoylethanolamide**

Palmitoylethanolamide exerts its diverse physiological effects through a complex interplay with multiple molecular targets and signaling pathways. Its mechanisms are not limited to a single receptor but involve a network of interactions that collectively contribute to its anti-inflammatory, analgesic, and neuroprotective actions.

### **2.1. Interaction with Peroxisome Proliferator-Activated Receptors (PPARs), particularly PPAR- $\alpha$**

A primary and extensively studied mechanism of PEA action involves the activation of Peroxisome Proliferator-Activated Receptors (PPARs), a family of nuclear receptors. PEA is recognized as an endogenous ligand for these receptors, with PPAR- $\alpha$  being a principal target.<sup>1</sup>

The activation of PPAR- $\alpha$  by PEA typically involves the binding of PEA to the receptor, leading to its internalization. Once internalized, the PEA-PPAR- $\alpha$  complex can

heterodimerize with Retinoid X Receptors (RXR) in the cell nucleus. This heterodimer then binds to specific DNA sequences known as PPAR-response elements (PPREs) in the promoter regions of target genes, thereby modulating their expression.<sup>1</sup> This genomic pathway results in a cascade of downstream effects, including the reduced production of pro-inflammatory cytokines, inhibition of mast cell degranulation, decreased microglial activation, and attenuation of oxidative stress.<sup>11</sup> These actions are central to PEA's anti-inflammatory and cytoprotective capabilities. While PPAR- $\alpha$  is the most characterized target, evidence also suggests that PEA can stimulate other PPAR isoforms, such as PPAR- $\gamma$  and PPAR- $\delta$ , which may further contribute to its broad anti-inflammatory profile.<sup>2</sup>

Interestingly, PEA's interaction with PPAR- $\alpha$  is not solely confined to these time-consuming genomic mechanisms. Research indicates that PEA can also elicit rapid analgesic effects through non-genomic (non-transcriptional) pathways mediated by PPAR- $\alpha$ .<sup>1</sup> These rapid effects are thought to involve the modulation of ion channels, such as medium and large calcium channels, potentially through a PPAR- $\alpha$  activation complex interacting with other signaling proteins, independent of direct gene transcription.<sup>1</sup> This dual mode of PPAR- $\alpha$  activation—both genomic and non-genomic—provides a compelling basis for understanding how PEA can exert both rapid symptomatic relief (e.g., pain reduction) and sustained therapeutic effects (e.g., resolution of inflammation and tissue repair via changes in gene expression). This multifaceted engagement with PPAR- $\alpha$  is a significant characteristic contributing to its therapeutic versatility.

## **2.2. Modulation of the Endocannabinoid System (ECS) and Related Signaling Pathways**

PEA is considered a member of the "extended endocannabinoid system" or an "endocannabinoid-like" compound, sharing structural similarities and metabolic pathways with classical endocannabinoids like anandamide (N-arachidonylethanolamine, AEA).<sup>3</sup> However, its interaction with the ECS is primarily indirect.

### **2.2.1. The "Entourage Effect" and Indirect Cannabinoid Receptor Modulation**

PEA exhibits low or negligible direct binding affinity for the canonical cannabinoid receptors, CB1 and CB2.<sup>3</sup> Instead, its influence on the ECS is largely attributed to the "entourage effect".<sup>1</sup> This phenomenon describes how PEA can enhance the levels and actions of endogenous cannabinoids, particularly AEA. One key mechanism underlying this effect is the inhibition of AEA degradation. PEA may compete with AEA for the catalytic site of fatty acid amide hydrolase (FAAH), the primary enzyme responsible for AEA breakdown, or modulate other enzymes involved in endocannabinoid metabolism.<sup>1</sup> By reducing AEA degradation, PEA effectively increases the concentration and prolongs the action of AEA at CB1 and CB2 receptors, as well as other targets like TRPV1 channels.<sup>2</sup>

Furthermore, PEA can indirectly influence CB2 receptor signaling by increasing the expression of CB2 receptors on inflammatory cells. This upregulation is thought to be dependent on PPAR- $\alpha$  activation, linking these two major signaling pathways of PEA.<sup>12</sup>

This "entourage effect" represents a sophisticated homeostatic amplification mechanism. By modulating the levels and actions of *endogenously* produced cannabinoids like AEA<sup>1</sup>, PEA does not act as a direct, potentially overwhelming exogenous agonist. Instead, it amplifies existing physiological signaling pathways that are often upregulated in areas of inflammation or injury where endocannabinoid production is naturally increased. This indirect mode of action could contribute to a more nuanced and potentially safer therapeutic profile compared to direct CB receptor agonists, which can be associated with significant psychoactive or systemic side effects.

### **2.2.2. Engagement with GPR55, GPR119, and TRPV1 Channels**

Beyond its influence on PPARs and the classical ECS receptors, PEA interacts with several other important signaling molecules. These include the orphan G protein-coupled receptors GPR55 and GPR119.<sup>1</sup> Activation of GPR55 by PEA, for instance, has been implicated in anti-anaphylactic effects, potentially through actions on mast cells.<sup>15</sup>

PEA also interacts with Transient Receptor Potential Vanilloid type-1 (TRPV1) channels.<sup>2</sup> TRPV1 channels are well-known for their role in nociception and

inflammation. PEA may modulate TRPV1 activity by desensitizing these channels on sensory neurons or by potentiating the action of AEA at TRPV1 sites.<sup>10</sup>

The engagement of PEA with multiple targets such as GPR55, GPR119, and TRPV1<sup>1</sup> indicates that its mechanisms of action are broad and extend beyond PPARs and indirect CB receptor modulation. Each of these additional targets is involved in distinct physiological processes, including pain transmission, inflammation, and metabolic regulation. This molecular promiscuity<sup>2</sup>, rather than being a limitation, suggests that PEA can address complex pathological conditions with multiple contributing factors by simultaneously modulating several relevant pathways. This characteristic is particularly relevant for its potential utility in conditions like neuropathic pain or chronic inflammatory disorders, which are often multifactorial.

## **2.3. Core Anti-inflammatory and Neuroprotective Actions**

The anti-inflammatory and neuroprotective effects of PEA are hallmarks of its biological activity and stem from its ability to modulate key cellular players and signaling cascades involved in these processes.

### **2.3.1. Influence on Mast Cell and Glial Cell Activity**

A critical aspect of PEA's mechanism is its profound influence on non-neuronal cells, particularly mast cells and glial cells (microglia and astrocytes). Mast cells, strategically located at sites interfacing with the external environment and near nerve endings, are key initiators and amplifiers of inflammatory and allergic responses. PEA effectively inhibits mast cell degranulation, thereby reducing the release of preformed and newly synthesized pro-inflammatory mediators such as histamine, TNF- $\alpha$ , and various interleukins.<sup>2</sup> This mast cell-stabilizing effect is a cornerstone of its anti-inflammatory action and aligns with its role as an ALIAmide.<sup>7</sup>

In the central nervous system, PEA modulates the activity of glial cells. Microglia, the resident immune cells of the CNS, and astrocytes play crucial roles in neuroinflammation. Dysregulated activation of these cells contributes to the pathogenesis of neuropathic pain and neurodegenerative diseases.<sup>12</sup> PEA has been

shown to reduce microglial activation and can promote a shift in microglia from a pro-inflammatory (M1) phenotype towards an anti-inflammatory, neuroprotective, and tissue-repair (M2) phenotype.<sup>10</sup>

The modulation of these non-neuronal cells—mast cells and glia—is central to PEA's neuroprotective and anti-inflammatory effects. These cells are key drivers and amplifiers of inflammatory and pain processes, especially within the nervous system.<sup>7</sup> PEA's ability to directly stabilize mast cells<sup>14</sup> and guide microglia towards a protective M2 phenotype<sup>17</sup> means it can interrupt the inflammatory cascade at a crucial cellular level, often upstream of direct neuronal damage. This is particularly significant for its efficacy in conditions like neuropathic pain, post-viral olfactory loss, and potentially glaucoma, where neuroinflammation is a core pathogenic component.

### **2.3.2. Attenuation of Pro-inflammatory Cytokines, Oxidative Stress, and Nociceptive Signaling**

Consistent with its effects on immune cells and PPAR- $\alpha$  activation, PEA leads to a significant reduction in the synthesis and release of a broad range of pro-inflammatory cytokines, including Tumor Necrosis Factor-alpha (TNF- $\alpha$ ), Interleukin-1beta (IL-1 $\beta$ ), IL-6, and IL-8, as well as various chemokines.<sup>2</sup>

PEA also exhibits important antioxidant effects, contributing to the reduction of oxidative stress, a common feature in inflammatory and degenerative conditions.<sup>1</sup> This is complemented by its ability to inhibit the activation of Nuclear Factor-kappa B (NF- $\kappa$ B), a key transcription factor that orchestrates the expression of numerous inflammatory genes, including those for cytokines, chemokines, and adhesion molecules.<sup>2</sup> Furthermore, PEA has been shown to reduce the expression of pro-inflammatory enzymes such as cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS).<sup>2</sup>

In the context of pain, PEA's analgesic effects are mediated by its ability to reduce both peripheral and central sensitization, which are key mechanisms underlying the development and maintenance of chronic pain states.<sup>10</sup>

To provide a consolidated overview of PEA's complex pharmacology, Table 2.1 summarizes its key molecular targets and associated biological outcomes. This table is crucial for understanding how PEA achieves its pleiotropic effects by interacting

with a diverse array of cellular components.

**Table 2.1: Key Molecular Targets and Signaling Pathways of Palmitoylethanolamide**

Target	Primary Effect	Key Biological Outcome	Selected Key References
PPAR-α	Direct Agonism	Anti-inflammatory gene expression, neuroprotection, analgesia, reduced mast cell degranulation, reduced microglial activation	1
FAAH (indirect via AEA)	Competitive inhibition (potential)	Increased AEA levels, enhanced endocannabinoid tone ("entourage effect"), analgesia, anti-inflammation	1
GPR55	Agonism	Modulation of inflammation, potential anti-anaphylactic effects (mast cells), role in aqueous humor outflow	1
GPR119	Agonism	Potential metabolic and anti-inflammatory effects	1
TRPV1 Channels	Modulation (desensitization, potentiation of AEA)	Analgesia, modulation of neurogenic inflammation	3
Mast Cells	Inhibition of degranulation, stabilization	Reduced release of inflammatory mediators (histamine, TNF-α),	11



		anti-inflammatory, anti-allergic, analgesic effects	
Microglia	Modulation of activity, promotion of M2 phenotype	Reduced neuroinflammation, neuroprotection, tissue repair	11
NF-κB Signaling Pathway	Inhibition of activation	Decreased expression of pro-inflammatory genes (cytokines, COX-2, iNOS)	2
Pro-inflammatory Cytokines	Reduction in synthesis/release (e.g., TNF-α, IL-6)	Decreased inflammation, reduced pain sensitization	2

## Chapter 3: Pharmaceutical Formulations and Pharmacokinetics of PEA

The therapeutic efficacy of Palmitoylethanolamide is significantly influenced by its physicochemical properties and, consequently, its pharmaceutical formulation. Understanding these aspects is crucial for optimizing its clinical application.

### 3.1. Comparative Analysis: Standard PEA versus Micronized and Ultramicronized PEA (um-PEA)

Native, or standard, PEA presents considerable formulation challenges due to its highly lipophilic nature. It is practically insoluble in water and demonstrates poor solubility in most other aqueous solvents, with a reported logarithm of its partition coefficient (log P) greater than 5.<sup>20</sup> This poor solubility often leads to dissolution-rate-limited oral absorption, potentially restricting its systemic

bioavailability and clinical effectiveness when administered in its naïve form.<sup>20</sup>

To overcome these limitations, pharmaceutical processing techniques such as micronization and ultram micronization have been developed and patented.<sup>4</sup> Micronized PEA (PEA-m) typically has particle sizes in the range of 2-10 micrometers (µm), while ultram micronized PEA (PEA-um) features even smaller particle sizes, generally between 0.8-6 µm.<sup>4</sup>

The reduction in particle size achieved through these techniques has significant implications for PEA's bioavailability, absorption, and subsequent clinical efficacy. By increasing the surface area of the PEA particles, micronization and ultram micronization enhance the dissolution rate in gastrointestinal fluids, which is a prerequisite for absorption.<sup>20</sup> Animal studies have corroborated these benefits; for instance, PEA-um demonstrated superior oral efficacy compared to naïve PEA in models such as carrageenan-induced paw edema in rats.<sup>20</sup> Pharmacokinetic studies in rats using isotopically labeled PEA ([<sup>13</sup>C]4-PEA) have shown that orally administered PEA-um results in higher overall plasma levels compared to naïve PEA, directly indicating greater absorbability.<sup>20</sup>

A particularly important characteristic attributed to ultram micronized PEA is its potential to cross the blood-brain barrier (BBB).<sup>4</sup> While improved intestinal absorption due to increased dissolution is a primary benefit of micronization<sup>20</sup>, the ability of um-PEA to penetrate the CNS is a critical distinction. This suggests that PEA-um may possess enhanced efficacy for central nervous system conditions not only due to higher systemic bioavailability but also as a result of direct access to central targets. This has profound implications for its application in treating neuroinflammatory and neurodegenerative disorders. Consequently, micronized and ultram micronized forms of PEA are predominantly the formulations used in clinical trials and are available as medical foods or dietary supplements.<sup>6</sup>

### **3.2. Advanced Co-formulations: um-PEA with Luteolin (umPEALUT)**

To potentially enhance the therapeutic effects of PEA, advanced co-formulations have been developed. One such formulation combines ultram micronized PEA with luteolin (umPEALUT). Luteolin is a naturally occurring bioflavonoid known for its potent antioxidant and anti-inflammatory properties.<sup>17</sup> It is recognized for its ability to reduce

reactive oxygen species (ROS) and may also contribute to improved microcirculation.<sup>17</sup>

The rationale for this combination lies in the potential for synergistic effects. In conditions such as post-COVID-19 olfactory loss, where neuroinflammation and oxidative stress in the olfactory bulbs and neuro-epithelium are implicated, the umPEALUT formulation is thought to offer a dual mechanism of action.<sup>17</sup> The PEA component primarily targets neuroinflammation, for example, by promoting an anti-inflammatory M2 phenotype in microglia, while the luteolin component directly addresses oxidative stress by scavenging ROS.<sup>17</sup>

This umPEALUT formulation has been primarily investigated for its efficacy in olfactory dysfunction, particularly following COVID-19 infection, and is also under investigation for tinnitus.<sup>17</sup> The combination represents a multi-targeted approach to conditions where both neuroinflammation and oxidative stress are key pathological contributors. PEA itself primarily targets inflammatory pathways and immune cell modulation.<sup>11</sup> The addition of luteolin introduces a strong antioxidant dimension.<sup>17</sup> Given that neuroinflammation and oxidative stress are often intricately linked in pathological processes, especially within the nervous system, combining um-PEA with luteolin allows the formulation to simultaneously address both these critical components. This may lead to greater therapeutic efficacy than either agent could achieve alone, particularly in complex conditions like post-viral olfactory loss where both mechanisms are clearly implicated.

### **3.3. Advanced Co-formulations: PEA with Alpha-Lipoic Acid (ALA)**

Another co-formulation strategy involves combining PEA with Alpha-Lipoic Acid (ALA). ALA is a well-established and potent antioxidant with both water- and fat-soluble properties, capable of regenerating other endogenous antioxidants such as glutathione and vitamins C and E.<sup>30</sup>

The rationale for combining PEA with ALA is again based on achieving synergistic effects, particularly in conditions characterized by significant inflammation and oxidative stress. An in-vitro study using a model of lipopolysaccharide (LPS)-stimulated human epithelial lung cells, designed to mimic aspects of the cytokine storm seen in severe infections like COVID-19, demonstrated that a combination of ALA and PEA could significantly reduce levels of ROS and nitric oxide (NO), and modulate the expression of major cytokines implicated in COVID-19

pathology.<sup>30</sup> These findings suggest a potential role for the PEA-ALA combination in counteracting severe inflammatory damage and mitigating cytokine storms.<sup>30</sup>

This combination has been investigated for its potential in respiratory inflammation, particularly in the context of COVID-19, and also holds relevance for neuropathic pain conditions, such as diabetic neuropathy, where ALA is already used for its neuroprotective and antioxidant effects.<sup>10</sup> One study evaluating a complex formulation containing ten elements, including PEA and ALA, reported improvements in pain, vibration perception threshold, and vitamin B12 levels in individuals with diabetic neuropathy.<sup>31</sup> It is important to note, however, that one study on olfactory dysfunction used ALA in a control group at a dosage considered too low to exert significant systemic anti-inflammatory or antioxidant effects, with the aim of isolating the effects of umPEALUT.<sup>26</sup> This contrasts with studies specifically designed to leverage the synergistic potential of higher, therapeutically relevant doses of ALA in combination with PEA.

PEA-ALA combinations thus offer a dual therapeutic approach. PEA's primary strength lies in its anti-inflammatory and immunomodulatory actions <sup>1</sup>, while ALA provides robust antioxidant defense.<sup>30</sup> In conditions such as COVID-19-induced lung injury or diabetic complications, where both excessive inflammation and oxidative damage are key pathological drivers, this combination allows for a two-pronged strategy: PEA works to dampen the inflammatory response and cytokine release, while ALA mitigates the concurrent oxidative stress. Such synergy could prove more effective than monotherapy in these complex, multifactorial diseases.

Table 3.1 provides a comparative overview of these PEA formulations, highlighting their characteristics and primary areas of investigation. This table is essential for understanding the pharmaceutical evolution aimed at overcoming PEA's inherent pharmacokinetic limitations and enhancing its therapeutic utility.

**Table 3.1: Comparative Overview of Palmitoylethanolamide Formulations**

Formulation	Particle Size / Key Adjuvant(s)	Reported Bioavailability/Absorption/Distribution Characteristics	Primary Studied Indications	Selected Key References
Naïve PEA	Large, variable (e.g., 100 µm to 2000 µm)	Poor water solubility, dissolution-rate	Historically used, basis for comparison	<sup>20</sup>

		-limited absorption, potentially low bioavailability		
Micronized PEA (PEA-m)	2–10 $\mu\text{m}$	Improved dissolution rate and absorption compared to naïve PEA, enhanced bioavailability	Chronic pain, inflammation, neuropathic pain, fibromyalgia, migraine, osteoarthritis	20
Ultramicronized PEA (PEA-um)	0.8–6 $\mu\text{m}$	Superior oral efficacy and absorbability compared to naïve PEA, potential to cross blood-brain barrier	Neuroinflammation, glaucoma, chronic pain, post-COVID olfactory dysfunction (as part of umPEALUT)	4
um-PEA with Luteolin (umPEALUT)	um-PEA + Luteolin (antioxidant bioflavonoid)	Combines um-PEA's improved bioavailability with luteolin's properties	Post-COVID olfactory dysfunction, tinnitus, conditions involving neuroinflammation and oxidative stress	17
PEA with Alpha-Lipoic Acid (ALA)	PEA (micronization status may vary) + ALA (potent antioxidant)	Combines PEA's actions with ALA's antioxidant effects	Respiratory inflammation (COVID-19), neuropathic pain (e.g., diabetic neuropathy), conditions with inflammation & oxidative stress	30

## **Chapter 4: Palmitoylethanolamide in Ocular Health and Disease**

Palmitoylethanolamide has garnered significant interest for its potential therapeutic applications in various ocular conditions, primarily owing to its anti-inflammatory, neuroprotective, and intraocular pressure (IOP)-lowering properties. Glaucoma and diabetic retinopathy are two key areas where PEA's effects are being investigated.

### **4.1. Therapeutic Potential of PEA in Glaucoma**

Glaucoma is a group of eye diseases characterized by progressive damage to the optic nerve, often, but not always, associated with elevated IOP. It is a leading cause of irreversible blindness worldwide.<sup>6</sup> Interestingly, PEA is an endogenous compound found naturally within ocular tissues, including the ciliary body, which is involved in aqueous humor production and IOP regulation. Studies have indicated that eyes affected by glaucoma tend to have lower levels of PEA in the ciliary body compared to healthy eyes, suggesting a potential role for PEA in ocular homeostasis.<sup>6</sup>

#### **4.1.1. Impact on Intraocular Pressure Regulation**

A substantial body of clinical evidence supports the ability of PEA to reduce IOP in glaucoma patients.<sup>6</sup> Oral administration of PEA, typically in micronized or ultramicronized forms (e.g., 300 mg twice daily or 600 mg once daily), has been shown to provide an additional IOP-lowering effect when used as an adjunct to conventional glaucoma medications like timolol eye drops.<sup>6</sup> One randomized clinical trial reported that adjunctive PEA therapy led to a further 16% reduction in IOP compared to timolol alone.<sup>6</sup>

PEA's efficacy in lowering IOP is not limited to high-pressure glaucoma; it has also demonstrated benefits in patients with low-pressure or normal-tension glaucoma (NTG).<sup>6</sup> In a trial involving NTG patients, ultramicronized PEA (300 mg twice daily) reduced mean IOP from approximately 14 mmHg to 11 mmHg after six months of treatment.<sup>6</sup> Furthermore, pre-treatment with PEA has been found to be effective in

preventing transient IOP spikes that can occur after procedures like laser iridotomy.<sup>6</sup>

#### **4.1.2. Underlying Mechanisms: Enhancement of Aqueous Humor Outflow and Optic Nerve Neuroprotection**

The IOP-lowering effect of PEA is, at least in part, attributable to its ability to enhance aqueous humor outflow.<sup>19</sup> Studies have demonstrated that PEA increases outflow facility in a concentration-dependent manner. This mechanism appears to involve the G protein-coupled receptor GPR55 and the nuclear receptor PPAR- $\alpha$ , with downstream signaling mediated via the p42/44 mitogen-activated protein kinase (MAPK) pathway within the cells of the trabecular meshwork, a key structure in the aqueous outflow system.<sup>19</sup>

Beyond its effects on IOP, PEA is also valued for its potential neuroprotective actions on the optic nerve and retinal ganglion cells (RGCs), the neurons primarily affected in glaucoma. Clinical studies suggest that PEA may help preserve or even improve visual field parameters and RGC function.<sup>6</sup> These neuroprotective effects are thought to stem from its broad anti-inflammatory properties, its ability to inhibit chronic inflammatory cascades, and its capacity to protect neural cells from various insults.<sup>8</sup> For instance, PEA can inhibit the overactivation of Müller glia in the retina, thereby reducing the release of pro-inflammatory molecules and cytokines that can contribute to RGC damage.<sup>8</sup>

The dual mechanism of PEA—simultaneously lowering IOP and providing direct neuroprotection—makes it a uniquely promising agent for glaucoma management. Glaucoma pathogenesis is complex, involving both IOP-dependent mechanical stress on the optic nerve and IOP-independent neurodegenerative processes.<sup>6</sup> Many conventional glaucoma treatments primarily focus on IOP reduction. PEA, by addressing both these critical aspects through enhancing aqueous outflow<sup>19</sup> and offering direct neuroprotection to RGCs<sup>6</sup>, may provide more comprehensive therapeutic benefits. This is particularly relevant for conditions like normal-tension glaucoma, where optic nerve damage occurs despite IOP levels being within the statistically normal range, highlighting the importance of IOP-independent neuroprotective strategies.

Recommended dosages for PEA in glaucoma generally range from 600 mg daily, with potential increases to 1200 mg daily for advanced cases. Micronized or

ultramicrosized formulations are preferred due to their enhanced absorption and bioavailability.<sup>6</sup> Importantly, PEA has demonstrated a favorable safety profile in ophthalmic studies, being well-tolerated with no significant adverse effects or drug interactions reported.<sup>6</sup>

## **4.2. Investigational Role of PEA in Diabetic Retinopathy**

Diabetic retinopathy (DR) is a common and serious complication of diabetes, characterized by damage to the blood vessels of the retina, leading to vision loss. The pathogenesis of DR involves chronic inflammation, neurodegeneration, and vascular dysfunction—processes that PEA has been shown to modulate.<sup>8</sup>

Endogenous levels of endocannabinoids and related compounds, including PEA, have been found to be altered in various ocular pathologies, including DR.<sup>32</sup> For example, one study reported that aqueous humor concentrations of PEA are significantly higher in women compared to men, and in female diabetic patients, levels of 2-arachidonoylglycerol (2-AG), another endocannabinoid, are higher in those with DR compared to those without.<sup>32</sup> These findings of altered endocannabinoid tone in diabetic retinopathy suggest a potential homeostatic imbalance within the eye that PEA supplementation could help restore. This aligns with PEA's role as an ALIAmide, an endogenous modulator that is upregulated in response to injury or disease to counteract local pathology. Supplementing with PEA could therefore act as a restorative therapy, bolstering the compromised endogenous anti-inflammatory and neuroprotective responses within the diabetic eye, rather than simply imposing an external pharmacological effect.

Preclinical evidence supports a potential role for PEA in DR. It has been shown to inhibit Toll-like receptor 4 (TLR-4) activity and downregulate TLR-4-triggered inflammatory pathways, which are implicated in the development and progression of DR.<sup>8</sup> In animal models of retinal disease, PEA administration has been associated with reduced inflammation, inhibition of neovascularization (a hallmark of advanced DR), suppression of pro-fibrotic changes, and attenuation of Müller gliosis. These beneficial effects are often linked to an increase in PPAR- $\alpha$  expression in retinal tissues.<sup>8</sup>

While direct clinical evidence from large-scale trials specifically evaluating PEA for DR endpoints is less extensive than for glaucoma, its well-established anti-inflammatory



and neuroprotective mechanisms, coupled with promising preclinical data, suggest a strong therapeutic potential.<sup>8</sup>

### 4.3. Critical Appraisal of Clinical Evidence for PEA in Ophthalmic Applications

The strength of clinical evidence for PEA in ophthalmic applications varies. For **glaucoma**, there is a moderate to strong evidence base supporting its use, particularly as an adjunctive therapy. Several double-blind, placebo-controlled studies have demonstrated its efficacy and safety in reducing IOP and have provided encouraging data on its potential neuroprotective effects.<sup>6</sup> The mechanistic understanding of how PEA enhances aqueous humor outflow via GPR55, PPAR- $\alpha$ , and MAPK signaling is also relatively well-defined.<sup>19</sup>

For **diabetic retinopathy**, the evidence is currently more inferential. While the mechanistic rationale is strong, based on PEA's known anti-inflammatory and neuroprotective actions and supportive preclinical data<sup>8</sup>, direct clinical trial evidence specifically assessing PEA's impact on DR progression, visual acuity, or retinal structural changes is still needed.

For both conditions, while existing studies are promising, there is a clear need for larger, longer-duration randomized controlled trials. Such trials would be invaluable for confirming long-term benefits, such as sustained visual field preservation in glaucoma, a slowdown in the progression of diabetic retinopathy, and a more definitive understanding of PEA's impact on overall disease course and patient-reported outcomes.

## Chapter 5: Palmitoylethanolamide in Auditory System Disorders

The application of Palmitoylethanolamide, particularly in its co-formulation with luteolin (umPEALUT), is an emerging area of investigation for auditory system disorders, with tinnitus being a primary focus. The rationale stems from PEA's known anti-inflammatory, neuroprotective, and immunomodulatory properties, which may address underlying pathological mechanisms contributing to certain hearing

conditions.

### **5.1. umPEALUT in the Management of Tinnitus: Rationale and Current Clinical Investigations**

Tinnitus, the perception of sound in the absence of an external acoustic stimulus, is a common and often distressing condition with diverse etiologies. Its pathophysiology can involve damage to the sensory hair cells within the cochlea (peripheral origin), potentially arising from trauma, vascular compromise, ototoxic agents, or systemic diseases.<sup>22</sup> However, tinnitus can also persist and become chronic due to maladaptive changes in the central auditory pathways, often involving neuroinflammation and altered neuronal excitability in upper auditory areas of the brain.<sup>22</sup> Reactive oxygen species (ROS) and inflammation are considered common denominators in many forms of cochlear damage and subsequent tinnitus development.<sup>22</sup>

The rationale for investigating umPEALUT in tinnitus management is based on the complementary actions of its two components. Palmitoylethanolamide is known to modulate the activity of mast cells, macrophages, and microglia, thereby exerting neuro-immuno-modulating and anti-inflammatory effects.<sup>12</sup> Luteolin, a bioflavonoid, contributes potent antioxidant properties by scavenging ROS and may also improve microcirculation, which can be compromised in certain inner ear pathologies.<sup>17</sup> This combination, therefore, aims to target both the inflammatory and oxidative stress pathways implicated in the development and perpetuation of tinnitus.

A significant clinical investigation in this area is the TiniPEA trial. This is designed as a longitudinal, randomized, placebo-controlled, triple-blind study aiming to evaluate the efficacy of umPEALUT in approximately 100 adult participants with tinnitus.<sup>22</sup> The trial compares two active treatment arms (umPEALUT at 1 sachet per day or 2 sachets per day) against a placebo group, with a treatment duration of 60 days. The primary outcomes are expected to be changes in tinnitus severity and impact, assessed using validated tinnitus evaluation questionnaires, as well as objective measures from audiometric examinations and acuphenometry, evaluated at baseline, 3 months, and 6 months.<sup>22</sup> The expected results, as per the trial registration, are an improvement in tinnitus symptoms in the umPEALUT-treated groups, attributed to the anti-ROS action of luteolin and the neuro-immuno-modulating action of PEA.<sup>22</sup> It is important to note that, as of the information available, these are anticipated outcomes, and published results from this specific trial were not found within the provided research materials.

Other snippets referencing tinnitus trial results <sup>33</sup> pertain to different interventions (e.g., neuromodulation devices) and are not related to PEA or umPEALUT. Similarly, general clinical trial updates <sup>35</sup> do not refer to the TiniPEA study.

The design of the TiniPEA trial appears to thoughtfully address the multifaceted nature of tinnitus. Given that tinnitus can originate from cochlear damage (peripheral mechanisms) but often becomes chronic due to central neuroinflammatory changes and maladaptive plasticity <sup>22</sup>, the umPEALUT formulation is hypothesized to act on both these levels. PEA's established neuro-immunomodulatory effects <sup>12</sup> could target central neuroinflammation, while luteolin's antioxidant and potential microcirculation benefits <sup>22</sup> might address peripheral cochlear health. The trial's combined use of subjective patient-reported outcomes (questionnaires) and objective audiological measures (audiometry, acuphenometry) <sup>22</sup> will be crucial in discerning the extent to which umPEALUT affects the perception of tinnitus versus underlying auditory pathway function.

## 5.2. Putative Mechanisms of PEA in Mitigating Auditory Pathologies

Based on its known biological activities, PEA (and its combination with luteolin) could mitigate auditory pathologies through several putative mechanisms:

- **Reduction of Neuroinflammation:** PEA may dampen inflammatory responses within the cochlea and central auditory pathways, which can be triggered by noise exposure, infection, or ototoxic insults. This involves modulating glial cell activity and cytokine production.
- **Mast Cell Modulation:** Mast cells are present in the inner ear and can contribute to inflammatory responses. PEA's ability to stabilize mast cells could reduce the release of inflammatory mediators that exacerbate auditory damage.
- **Antioxidant Effects:** Oxidative stress is a major contributor to age-related hearing loss and noise-induced hearing loss. The luteolin component of umPEALUT, and potentially PEA itself via PPAR- $\alpha$  pathways, could protect delicate auditory structures like hair cells and spiral ganglion neurons from ROS-induced damage.
- **Improved Microcirculation:** Adequate blood flow is essential for inner ear health. The luteolin in umPEALUT is suggested to improve microcirculation <sup>22</sup>, which could enhance nutrient and oxygen delivery to the cochlea and facilitate the removal of metabolic waste products.

- **Neuroprotection:** PEA's general neuroprotective properties may help preserve the function and survival of auditory neurons in the face of various stressors.

### 5.3. Evaluation of Current Scientific Evidence and Identification of Research Lacunae for Auditory Applications

The current scientific evidence for the use of PEA or umPEALUT specifically in tinnitus and other hearing loss conditions is still in its nascent stages. The primary support comes from the strong mechanistic rationale derived from PEA's known pharmacological profile and the design of ongoing clinical trials like TiniPEA.<sup>22</sup> Published results from large-scale, robust randomized controlled trials (RCTs) specifically evaluating PEA for tinnitus or other forms of hearing loss were not available in the provided research. An irrelevant snippet regarding peas and lentils for hearing health<sup>37</sup> does not contribute to the evidence for PEA.

Therefore, the evidence base for PEA in auditory disorders is, at present, largely mechanistically inferred and awaits rigorous clinical validation. While the rationale for using umPEALUT in tinnitus is compelling, based on its established anti-inflammatory and antioxidant properties<sup>22</sup>, direct clinical evidence specifically for auditory applications is still pending the outcomes of trials such as TiniPEA. This situation contrasts with other therapeutic areas for PEA, such as chronic pain or glaucoma, where a more substantial body of clinical data already exists.

Key research lacunae include:

- The need for published results from well-designed RCTs, such as the TiniPEA trial, to establish clinical efficacy and safety in tinnitus.
- Investigations into the potential of PEA or its formulations for other types of hearing loss (e.g., noise-induced, age-related, sudden sensorineural hearing loss).
- Further elucidation of the specific molecular targets and mechanisms of PEA within the auditory system.
- Determination of optimal dosing regimens and treatment durations for different auditory conditions.

This thesis must clearly highlight this current gap in high-level clinical evidence for auditory applications and underscore the importance of forthcoming trial results in

shaping the future therapeutic landscape for PEA in this domain.

## **Chapter 6: Palmitoylethanolamide and Olfactory Function**

The sense of smell, or olfaction, can be significantly impaired by various factors, with viral infections being a prominent cause of olfactory dysfunction. The COVID-19 pandemic brought unprecedented attention to this issue, as a substantial number of individuals experienced prolonged or chronic loss of smell (anosmia), reduced smell (hyposmia), or distorted smell (parosmia) as a sequela of SARS-CoV-2 infection.<sup>17</sup> Palmitoylethanolamide, particularly in the co-ultramicrosized formulation with luteolin (umPEALUT), has emerged as a promising therapeutic intervention for these conditions.

### **6.1. Efficacy of umPEALUT in Post-COVID-19 Olfactory Dysfunction**

Chronic olfactory dysfunction following COVID-19 is often linked to persistent neuroinflammation within the olfactory system, affecting the olfactory epithelium, olfactory bulb, and potentially higher olfactory centers in the brain.<sup>17</sup>

#### **6.1.1. Clinical Outcomes: Improvement in Anosmia, Hyposmia, and Parosmia**

Multiple clinical trials have investigated the efficacy of umPEALUT, frequently administered in conjunction with olfactory training (OT), for treating post-COVID-19 olfactory dysfunction. Olfactory training involves the regular, structured sniffing of a set of specific odorants to stimulate the olfactory system and promote recovery. The collective findings from these studies generally indicate that umPEALUT can significantly improve olfactory function in affected patients.<sup>11</sup>

Key outcomes reported include:

- **Improvement in Odor Identification Scores:** Patients treated with umPEALUT (often with OT) have shown statistically significant improvements in their ability to

identify odors, as measured by validated olfactory tests like the Sniffin' Sticks test or similar identification batteries.<sup>17</sup> For example, one longitudinal study reported that three months of umPEALUT therapy (with or without OT, depending on the randomization group) led to an average improvement of 10.7 points in validated odor identification scores from baseline.<sup>24</sup>

- **Superiority of Combined Therapy:** Several studies have demonstrated that the combination of umPEALUT and olfactory training yields better results than either OT alone or umPEALUT alone.<sup>17</sup> In one randomized trial, 89.2% of patients receiving combined therapy (once-daily umPEALUT plus OT) achieved a clinically significant improvement (defined as >3 points on an odor identification test) at 90 days. This was substantially higher than the improvement rates observed in groups receiving OT with placebo (36.8%), twice-daily umPEALUT alone (40%), or once-daily umPEALUT alone (41.6%).<sup>17</sup>
- **Reduction in Parosmia:** umPEALUT has also been associated with a reduction in the prevalence and severity of parosmia, a condition where familiar odors are perceived as distorted and often unpleasant.<sup>24</sup> However, the efficacy for parosmia may be more variable. One study suggested that while umPEALUT is useful for treating quantitative smell alterations (hyposmia/anosmia), which are thought to be linked to brain neuroinflammation, its effect on qualitative disorders like parosmia (potentially related to peripheral olfactory nerve or neuroepithelium damage) might be more limited.<sup>26</sup>
- **Benefits for Associated Symptoms:** Beyond olfactory recovery, umPEALUT treatment has also been reported to alleviate associated symptoms experienced by some Long COVID patients with olfactory loss, such as "mental clouding" or "brain fog," and to improve memory.<sup>24</sup>

## 6.2. Mechanistic Insights: Targeting Neuroinflammation within the Olfactory Bulb and Pathways

The proposed mechanism by which umPEALUT aids in olfactory recovery centers on its ability to target neuroinflammation within the olfactory system. The olfactory nerve, which transmits smell information from the nasal cavity to the brain, provides a direct pathway for pathogens like SARS-CoV-2 to access the central nervous system.<sup>38</sup> Viral infection can lead to damage and inflammation in the olfactory epithelium (where olfactory sensory neurons reside) and the olfactory bulb (the first relay station for olfactory information in the brain), potentially extending to higher olfactory processing

centers.<sup>17</sup> This neuroinflammatory response is considered a key driver of persistent olfactory dysfunction.

umPEALUT is thought to counteract this neuroinflammation through the synergistic actions of its components <sup>17</sup>:

- The **Palmitoylethanolamide (PEA)** component, particularly in its ultramicronized form which may enhance CNS penetration <sup>4</sup>, acts on microglial cells. PEA can modulate microglial activity, promoting a shift from a pro-inflammatory M1 state to an anti-inflammatory, neuroprotective, and tissue-repair M2 phenotype.<sup>17</sup> This helps to resolve inflammation and create a more favorable environment for neuronal recovery and regeneration.
- The **Luteolin (LUT)** component contributes by reducing reactive oxygen species (ROS).<sup>17</sup> Oxidative stress often accompanies inflammation and can further damage olfactory neurons and supporting cells. Luteolin's antioxidant action helps to mitigate this damage.

This dual action of addressing both neuroinflammation and oxidative stress targets key pathological processes underlying post-viral olfactory loss. The consistent finding that umPEALUT, a formulation designed to target these very processes <sup>17</sup>, improves olfactory function in post-COVID patients <sup>17</sup> strongly supports the hypothesis that persistent neuroinflammation is a critical driver of this sensory deficit. This, in turn, positions PEA (especially ultramicronized PEA capable of BBB penetration <sup>4</sup>) as a valuable therapeutic candidate for a range of CNS disorders characterized by neuroinflammation.

### 6.3. Strength and Limitations of Clinical Evidence for PEA in Olfactory Restoration

The scientific evidence supporting the use of umPEALUT for post-COVID-19 olfactory restoration, particularly when combined with olfactory training, can be considered **moderate to strong**.

- **Strengths:** The evidence is underpinned by multiple randomized controlled trials, some of which were double-blinded, consistently demonstrating statistically significant improvements in olfactory scores.<sup>17</sup> The mechanistic rationale, focusing on the anti-neuroinflammatory and antioxidant effects of umPEALUT, is clear and biologically plausible.
- **Limitations:** Some of the earlier studies may have had smaller sample sizes or



lacked a true placebo control for the umPEALUT component when combined with OT (i.e., comparing umPEALUT + OT versus OT alone, where OT itself is an active intervention).<sup>26</sup> As noted, the beneficial effect on parosmia might be less pronounced or consistent than that observed for quantitative smell loss (anosmia/hyposmia).<sup>26</sup> It is also important to acknowledge that not all patients achieve full recovery even with treatment; one report indicated that approximately 15% of treated patients do not achieve full recovery of a normal olfactory threshold, and almost 5% show no recovery at all.<sup>29</sup>

Furthermore, one study highlighted a nuanced perspective on clinical meaningfulness.<sup>27</sup> While their results showed that the group receiving umPEA-LUT plus OT had statistically significant improvements in odor discrimination and overall olfactory function scores (TDI score) where the OT alone group did not, the difference in

*clinically meaningful improvements* (often defined by a specific threshold of change) between the two groups was not found to be statistically significant. This finding, which contrasted with some previous studies, underscores the importance of standardized definitions for clinically meaningful outcomes in olfactory research and the need for continued investigation to clarify the magnitude of added benefit from umPEALUT over OT alone across diverse patient populations.

## **Chapter 7: Palmitoylethanolamide in Respiratory Inflammation and Infections**

Palmitoylethanolamide's established anti-inflammatory and immunomodulatory properties have led to its investigation as a potential therapeutic agent for various respiratory conditions, ranging from common viral infections like influenza to the more complex inflammatory sequelae of COVID-19.

### **7.1. Historical and Current Perspectives on PEA for Influenza and Upper Respiratory Tract Infections**



The exploration of PEA for respiratory infections is not entirely new. A series of six clinical trials were conducted and published in the 1970s, involving a substantial cohort of nearly 4000 individuals, which specifically studied PEA as a therapy for influenza and the common cold.<sup>3</sup> These early studies reported that PEA was both effective and safe, demonstrating benefits in both prophylactic (preventive) use and as a treatment for active infections.<sup>16</sup> The primary mechanism attributed to these effects at the time was its general anti-inflammatory action.<sup>5</sup>

While these historical trials provided initial positive signals, interest in this application of PEA somewhat waned, partly due to a lack of detailed understanding of its precise mechanisms of action. However, with the significant advancements in elucidating PEA's pharmacology over the past few decades—including the discovery of its interactions with PPARs, its role in the endocannabinoid system, and its modulation of mast cells—there has been a renewed interest in its potential for respiratory infections.<sup>5</sup>

These early positive clinical data on PEA for common viral respiratory infections, though generated before a comprehensive mechanistic understanding was available, provide a valuable historical precedent. This early evidence, when viewed in conjunction with current insights into PEA's broad anti-inflammatory and immunomodulatory effects<sup>7</sup>, lends considerable credibility to its re-evaluation and investigation for contemporary viral respiratory threats, including influenza and SARS-CoV-2.

## **7.2. PEA in the Context of COVID-19 Pathophysiology**

The emergence of COVID-19, caused by the SARS-CoV-2 virus, highlighted the devastating impact of severe respiratory inflammation, often characterized by "cytokine storms" and the development of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS).<sup>16</sup> PEA's known mechanisms position it as a candidate for mitigating these severe inflammatory responses.

### **7.2.1. Modulation of Cytokine Storms and Acute Lung Injury (PEA and PEA-ALA)**

A cytokine storm is an excessive immune response where high levels of pro-inflammatory cytokines are released, leading to widespread tissue damage, particularly in the lungs. PEA may help modulate these cytokine storms through several actions:

- Reducing the secretion of key pro-inflammatory cytokines such as IL-1 $\beta$ , IL-6, and TNF- $\alpha$ .<sup>15</sup>
- Inhibiting the expression of inducible nitric oxide synthase (iNOS) and the activation of the NF- $\kappa$ B pathway, which drives the transcription of many inflammatory genes.<sup>7</sup>
- Modulating the activity of mast cells, which can contribute to the inflammatory milieu in the lungs.<sup>16</sup>

The combination of PEA with alpha-lipoic acid (PEA-ALA) has also shown promise. An in-vitro study using human lung epithelial cells stimulated with lipopolysaccharide (LPS) to mimic viral-induced inflammation found that PEA-ALA significantly reduced the production of ROS, nitric oxide, and key cytokines implicated in COVID-19 pathogenesis. This suggests that the combination could be effective in counteracting inflammatory damage and blunting the cytokine storm.<sup>30</sup>

Animal models of ALI have further supported PEA's potential. Ultramicronized PEA (um-PEA) was shown to reduce lung injury by decreasing neutrophil infiltration, limiting mast cell recruitment to the lungs, and downregulating pro-inflammatory cytokines. These effects were associated with the modulation of critical intracellular signaling pathways, including pERK, pJNK, p38MAPK, and NF- $\kappa$ B.<sup>15</sup>

Preliminary clinical observations have also emerged. An observational case-control study involving patients with early-stage COVID-19 treated with a relatively high daily dose of PEA (1880 mg/day for 28 days) reported beneficial anti-inflammatory and modulatory effects. The treatment was associated with a reduction in the overall inflammatory state, decreased oxidative stress, and favorable changes in the coagulation cascade, which is often dysregulated in severe COVID-19.<sup>15</sup>

### **7.3. Immunomodulatory Mechanisms in the Respiratory Tract: Role of TLRs, PPARs, and Mast Cell Stabilization**

PEA's immunomodulatory effects in the respiratory tract are multifaceted, involving

interactions with key components of the innate and adaptive immune responses.

- **PPAR- $\alpha$  Activation:** As discussed previously, PEA is a PPAR- $\alpha$  agonist. Activation of PPAR- $\alpha$  in immune and epithelial cells can lead to the transrepression of pro-inflammatory genes and the upregulation of anti-inflammatory pathways, thereby ameliorating oxidative and nitrosative stress.<sup>16</sup>
- **Toll-Like Receptor (TLR) Modulation:** TLRs, such as TLR4, are pattern recognition receptors that play a crucial role in detecting viral components and initiating innate immune responses. However, overzealous TLR4 signaling can contribute to excessive inflammation and lung injury during viral infections.<sup>16</sup> PEA has been shown to modulate TLR4 signaling pathways, potentially dampening exaggerated inflammatory responses. For instance, PEA treatment demonstrated efficacy in a model of colitis via a TLR4/PPAR- $\alpha$  dependent mechanism, reducing inflammatory markers.<sup>16</sup> This suggests a similar modulatory role could be active in the lungs.<sup>8</sup>
- **Mast Cell Stabilization:** Mast cells are abundant in the respiratory tract and can be rapidly activated by viral infections, releasing a plethora of pro-inflammatory mediators (e.g., histamine, proteases, cytokines, chemokines) that contribute to airway inflammation, bronchoconstriction, and lung pathology.<sup>7</sup> PEA's well-documented ability to stabilize mast cells and inhibit their degranulation is a critical mechanism by which it can limit inflammatory damage in the respiratory system.<sup>7</sup>

The ability of PEA to modulate both innate immune sensors like TLRs and master regulators of inflammation such as PPARs and NF- $\kappa$ B, alongside its direct effects on key immune effector cells like mast cells, provides a comprehensive mechanistic framework for its capacity to attenuate respiratory viral inflammation. Viral respiratory infections trigger a complex immune cascade that begins with pathogen recognition by TLRs<sup>16</sup>, leading to the activation of transcription factors like NF- $\kappa$ B<sup>7</sup>, which in turn drive the production of cytokines and the recruitment and activation of various immune cells, including mast cells.<sup>7</sup> PEA appears to intervene at multiple critical junctures in this cascade: it can modulate TLR4 signaling<sup>16</sup>, activate PPAR- $\alpha$  which exerts anti-inflammatory transcriptional effects<sup>1</sup>, inhibit NF- $\kappa$ B activation<sup>7</sup>, and directly stabilize mast cells.<sup>14</sup> This multi-pronged approach is likely to be more effective in controlling the complex and often overwhelming inflammatory milieu of the lungs during severe viral infections than a therapeutic agent targeting only a single pathway.

## 7.4. Synthesis of Preclinical and Clinical Evidence for PEA in Respiratory Conditions

The evidence supporting PEA's use in respiratory conditions is varied:

- **Preclinical Evidence:** There is strong preclinical evidence from animal models and in-vitro studies demonstrating PEA's (and PEA-ALA's) anti-inflammatory and immunomodulatory effects in the context of lung injury and inflammation.<sup>15</sup> These studies provide a solid mechanistic basis for its potential utility.
- **Clinical Evidence:**
  - For **influenza and the common cold**, historical clinical trials from the 1970s reported positive outcomes.<sup>3</sup>
  - For **COVID-19**, the clinical evidence is still emerging. It currently consists mainly of promising observational data and case reports<sup>15</sup>, rather than results from large-scale, randomized controlled trials specifically evaluating PEA for acute COVID-19 treatment or prophylaxis.

While the historical and preclinical data are encouraging, there is a clear need for robust, modern RCTs to definitively establish the efficacy, optimal dosing regimens, and specific patient populations that would benefit most from PEA (or its co-formulations like PEA-ALA) in the context of contemporary respiratory viral infections such as influenza and COVID-19.

## Chapter 8: Comprehensive Synthesis and Comparative Evidentiary Analysis

This chapter synthesizes the findings from the preceding chapters to provide an integrated overview of Palmitoylethanolamide's efficacy across ocular, auditory, olfactory, and respiratory systems. It aims to critically compare the strength of scientific evidence for each therapeutic application, highlighting common mechanistic themes and acknowledging the role of specific formulations.

### 8.1. Integrated Overview of PEA's Efficacy Across Ocular, Auditory, Olfactory, and

## Respiratory Systems

Palmitoylethanolamide has demonstrated a broad spectrum of therapeutic potential across diverse physiological systems, largely attributable to its fundamental biological actions as an anti-inflammatory, neuroprotective, and immunomodulatory agent.

- In **ocular health**, PEA, particularly ultramicrosized PEA (um-PEA), shows promise in glaucoma by reducing intraocular pressure (via enhanced aqueous humor outflow involving GPR55 and PPAR- $\alpha$ ) and offering optic nerve neuroprotection. Its potential in diabetic retinopathy is based on similar anti-inflammatory and neuroprotective mechanisms, targeting pathways like TLR4 and Müller cell activation.
- In **auditory disorders**, the focus is primarily on tinnitus, with umPEALUT (um-PEA and luteolin) being investigated. The rationale involves PEA's neuro-immunomodulation and luteolin's antioxidant and microcirculatory benefits, targeting both peripheral cochlear and central auditory pathway pathologies.
- In **olfactory function**, umPEALUT has shown notable efficacy in improving post-COVID-19 olfactory dysfunction (anosmia, hyposmia, and parosmia), especially when combined with olfactory training. The mechanism centers on counteracting neuroinflammation in the olfactory bulb and pathways, with PEA modulating microglia and luteolin reducing oxidative stress.
- In **respiratory inflammation**, historical data supports PEA's use in influenza and common colds. For COVID-19, PEA (and its combination with ALA) is investigated for its potential to modulate cytokine storms and acute lung injury by inhibiting NF- $\kappa$ B, modulating TLRs and PPARs, and stabilizing mast cells.

Common mechanistic themes underpinning these diverse applications include the activation of PPAR- $\alpha$ , modulation of the extended endocannabinoid system (including GPR55 and TRPV1), stabilization of mast cells, and regulation of glial cell activity. The development of advanced formulations like um-PEA, umPEALUT, and PEA-ALA has been crucial in enhancing bioavailability and targeting specific aspects of disease pathology (e.g., oxidative stress with luteolin/ALA). PEA's pleiotropic actions make it a compelling candidate for various conditions that share underlying inflammatory, neurodegenerative, or immune dysregulation processes.

### 8.2. Comparative Assessment of the Strength of Scientific Evidence for Each Therapeutic Application

The strength of scientific evidence supporting PEA's use varies considerably across the investigated therapeutic areas, reflecting the maturity of research and the availability of high-quality clinical trial data for each specific indication. This variation is critical for guiding both current clinical considerations and future research directions.

- **Eyesight (Glaucoma):** The evidence for PEA (primarily um-PEA) in glaucoma can be rated as **Moderate to Strong**. This is supported by multiple randomized controlled trials (RCTs) demonstrating its efficacy in reducing intraocular pressure when used as an adjunctive therapy.<sup>6</sup> Furthermore, there is robust mechanistic evidence detailing its role in enhancing aqueous humor outflow through GPR55 and PPAR- $\alpha$  signaling<sup>8</sup>, alongside promising data on its neuroprotective effects on the optic nerve.<sup>6</sup>
- **Olfactory Function (Post-COVID-19 Olfactory Dysfunction):** The evidence for umPEALUT, particularly in combination with olfactory training (OT), is also **Moderate to Strong**. Several RCTs have reported significant improvements in olfactory scores (odor identification, discrimination) in patients with persistent post-COVID-19 olfactory loss.<sup>17</sup> The targeted mechanism—counteracting neuroinflammation in the olfactory system—is well-rationalized. However, some studies have raised questions about the magnitude of clinically meaningful improvement over OT alone, and efficacy for parosmia may be less consistent.<sup>26</sup>
- **Respiratory Inflammation:**
  - **Influenza and Common Cold:** The evidence here is best described as **Emerging/Historical**. Positive findings from clinical trials conducted in the 1970s exist<sup>3</sup>, but these studies lack the methodological rigor and detailed mechanistic insights of modern trials. While supportive, they necessitate contemporary validation.
  - **COVID-19 (Lung Inflammation/Cytokine Storm):** The evidence is currently **Emerging**. There is promising preclinical data from in-vitro and animal models for both PEA monotherapy and PEA-ALA combinations, suggesting potential to mitigate lung injury and cytokine storms.<sup>15</sup> Some supportive observational clinical data for PEA in early-stage COVID-19 also exists.<sup>15</sup> However, large-scale, well-controlled RCTs are lacking.
- **Hearing (Tinnitus):** The evidence for umPEALUT in tinnitus is **Limited/Emerging**. The therapeutic rationale, based on addressing neuroinflammation and oxidative stress in the auditory system, is sound.<sup>22</sup> However, the clinical evidence currently relies heavily on the design and anticipated outcomes of ongoing or planned trials, such as the TiniPEA study. As of now, published results from definitive RCTs

are not available in the provided materials.

This comparative assessment underscores that while PEA holds promise across a range of sensory and respiratory conditions, the level of clinical validation is not uniform. Glaucoma and post-COVID olfactory dysfunction have a more developed clinical research base, lending stronger support for consideration in clinical practice under appropriate guidance. For tinnitus and acute respiratory viral infections (including COVID-19 lung inflammation), while the mechanistic plausibility is high, the field awaits results from robust, contemporary clinical trials to establish definitive efficacy and safety. This variance highlights critical areas where future research investment is most needed to translate PEA's potential into evidence-based therapeutic options.

### **8.3. Consolidated Safety and Tolerability Profile of PEA and its Key Formulations**

Across the various therapeutic applications and dosages studied, Palmitoylethanolamide has consistently demonstrated a favorable safety and tolerability profile.

- PEA is generally reported as well-tolerated, even at relatively high doses (e.g., 600 mg to 1200 mg daily, with some studies using up to 1.8 g/day or higher in specific contexts like early COVID-19 treatment).<sup>3</sup>
- Serious adverse effects are rarely reported in clinical trials or observational studies. The most commonly noted side effect, when it occurs, is mild gastrointestinal discomfort, such as nausea, in a small subset of individuals.<sup>9</sup>
- No major or clinically significant drug-drug interactions have been documented in the literature reviewed, which is an important consideration for a compound often used adjunctively with other medications.<sup>6</sup>
- The safety of PEA during pregnancy and breastfeeding has not been well-established through rigorous clinical trials. Therefore, its use in these populations is typically approached with caution, often advising avoidance unless specifically recommended by a healthcare professional.<sup>9</sup>
- Micronized and ultram micronized formulations of PEA, which are commonly used to enhance bioavailability, have also demonstrated favorable safety profiles in preclinical toxicological studies, including genotoxicity assays and acute/repeat-dose oral toxicity studies.<sup>20</sup>



This generally benign safety profile is a significant advantage for PEA, particularly when considering its potential for long-term use in chronic conditions or as a supportive therapy.

Table 8.1 provides a summary of the clinical evidence for PEA across the investigated therapeutic areas, serving as a capstone for the comparative evidentiary analysis. This table synthesizes findings from Chapters 4-7, directly addressing the core thesis objective of comparing evidence strength.

**Table 8.1: Summary of Clinical Evidence for Palmitoylethanolamide Across Investigated Therapeutic Areas**

Therapeut ic Area	Specific Indication	PEA Formulatio n Used (Typical)	Key Clinical Trial(s) & Design (Example)	Primary Outcomes & Significan ce (Examples )	Overall Strength of Evidence	Selected Key Reference s
<b>Eyesight</b>	Glaucoma (IOP reduction, neuroprot ection)	um-PEA, PEA-m	Multiple RCTs, double-bli nd, placebo-c ontrolled (adjunctiv e) <sup>6</sup>	Significant additional IOP reduction (e.g., 16% with timolol, or from ~14 to ~11 mmHg in NTG); improved visual field parameter s in some studies.	Moderate to Strong	<sup>6</sup>
	Diabetic Retinopat hy	PEA (um-PEA likely)	Primarily preclinical data and mechanist ic rationale; limited direct	Preclinical : Reduced inflammati on, neovascu larization, Müller gliosis.	Emerging/ Limited	<sup>8</sup>



			clinical trial evidence for DR endpoints.	Clinical: Altered endocannabinoid levels in DR.		
<b>Hearing</b>	Tinnitus	umPEALUT	Ongoing/Planned RCTs (e.g., TiniPEA: longitudinal, randomized, placebo-controlled, triple-blind) <sup>22</sup>	<i>Expected: Improvement in tinnitus questionnaire scores and audiometric/acuphenometry measures. Published RCT results not yet available.</i>	Limited/Emerging	<sup>22</sup>
<b>Olfactory Function</b>	Post-COVID-19 Olfactory Dysfunction	umPEALUT	Multiple RCTs, some double-blind, often comparing umPEALUT+OT vs. OT alone or umPEALUT alone <sup>17</sup>	Significant improvement in odor identification scores (e.g., 89.2% on combined therapy had >3 point improvement vs. ~37-42% for monotherapies); reduction in parosmia; improved	Moderate to Strong	<sup>17</sup>

				mental clouding. Some debate on <i>clinically meaningful</i> / difference over OT alone. <sup>27</sup>		
<b>Respiratory Inflammation</b>	Influenza / Common Cold	PEA	Historical clinical trials (1970s), some controlled <sup>5</sup>	Reported prophylactic and therapeutic effects: reduced incidence, pain, fever episodes.	Emerging/ Historical	<sup>3</sup>
	COVID-19 (Lung Inflammation/Cytokine Storm)	PEA, PEA-ALA	Preclinical (in-vitro, animal models) <sup>15</sup> ; Observational clinical study (early COVID-19) <sup>15</sup>	Preclinical : Reduced ROS, NO, pro-inflammatory cytokines, lung injury. Observational: Reduced inflammation, oxidative stress, changes in coagulation. <i>Lacks large RCTs for acute COVID-19.</i>	Emerging	<sup>15</sup>

## Chapter 9: Conclusions and Future Perspectives

This thesis has undertaken a comprehensive examination of Palmitoylethanolamide (PEA), an endogenous fatty acid amide, focusing on its biological mechanisms and therapeutic applications in sensory (ocular, auditory, olfactory) and respiratory systems. The analysis covered its historical context, fundamental pharmacology, the significance of pharmaceutical formulations, and a critical appraisal of the scientific evidence supporting its use in various conditions.

### 9.1. Principal Findings and Their Implications for Clinical Practice

PEA exerts its biological effects through a multifaceted mechanism of action, primarily involving the activation of PPAR- $\alpha$ , indirect modulation of the endocannabinoid system via the "entourage effect," interaction with GPR55 and TRPV1 channels, and significant influence over mast cell and glial cell activity. These actions collectively underpin its well-documented anti-inflammatory, neuroprotective, and analgesic properties.

The development of advanced pharmaceutical formulations, such as micronized PEA (PEA-m), ultramicronized PEA (um-PEA), and co-formulations like um-PEA with luteolin (umPEALUT) or PEA with alpha-lipoic acid (ALA), has been pivotal. These formulations aim to overcome PEA's inherent poor water solubility and enhance its bioavailability, with um-PEA also showing potential for improved central nervous system penetration. This pharmaceutical evolution is critical for translating PEA's biological potential into tangible clinical benefits.

The strength of evidence for PEA's efficacy varies by indication:

- **Glaucoma:** um-PEA shows moderate to strong evidence as an adjunctive therapy for lowering intraocular pressure and offering potential neuroprotection. Its dual action is a significant advantage.
- **Post-COVID-19 Olfactory Dysfunction:** umPEALUT, combined with olfactory training, has moderate to strong evidence for improving olfactory function, underscoring the role of neuroinflammation in this condition.
- **Tinnitus:** The use of umPEALUT is emerging, with a strong mechanistic rationale but currently limited direct clinical trial evidence; results from ongoing studies are

keenly awaited.

- **Respiratory Inflammation:** Historical trials suggest PEA's utility in common viral infections. For COVID-19-related lung inflammation, preclinical and observational data for PEA and PEA-ALA are promising but require robust RCT validation.

PEA generally exhibits a favorable safety and tolerability profile across these applications, with few reported side effects and no major drug interactions, making it an attractive option, particularly for chronic conditions or as an adjunct to standard therapies.

The implications for clinical practice are that PEA, especially in its optimized formulations, can be considered a viable supportive therapy in conditions like glaucoma and post-COVID olfactory loss, where evidence is more established. For other indications, while promising, its use should be guided by emerging research and individual patient assessment.

## 9.2. Acknowledgment of Current Research Limitations and Unanswered Questions

Despite the promising findings, several limitations and unanswered questions remain in the field of PEA research:

- **Gaps in Clinical Trial Data:** For certain indications, particularly tinnitus, specific forms of hearing loss, and as a primary treatment or robust prophylactic for acute respiratory viral illnesses like influenza and COVID-19, there is a need for more large-scale, rigorously designed RCTs.
- **Long-Term Studies:** While safety appears good in short to medium-term studies (up to a few months), more long-term data (years) are needed across all applications to confirm sustained efficacy and safety with chronic use.
- **Mechanistic Elucidation:** While key mechanisms are known, further research is needed to fully elucidate the specific molecular interactions, downstream signaling cascades, and the relative contribution of each pathway to PEA's effects in different tissues and disease states.
- **Optimal Dosing and Duration:** Optimal dosing regimens and treatment durations for various conditions and patient populations are not always definitively established and may require further investigation and personalization.
- **Formulation Comparisons:** Head-to-head comparative clinical trials of different

PEA formulations (e.g., naïve vs. micronized vs. ultramicronized; PEA monotherapy vs. co-formulations like umPEALUT or PEA-ALA) would be valuable to guide formulation choice.

- **Biomarkers of Response:** Identifying biomarkers that could predict which patients are most likely to respond to PEA therapy would enhance its targeted application and improve treatment outcomes.
- **Heterogeneity of Conditions:** Conditions like tinnitus or Long COVID are heterogeneous. Future research should aim to identify patient subgroups that may benefit most from PEA.

### 9.3. Strategic Recommendations for Future Preclinical Research, Clinical Trials, and Therapeutic Development of PEA

To further advance the therapeutic development and clinical application of PEA, the following strategic recommendations are proposed:

- **Prioritize Rigorous Clinical Trials:** Focus on conducting well-designed, large-scale, placebo-controlled (and active-comparator) RCTs for indications where preliminary data is promising but definitive evidence is lacking. This includes:
  - Following up on and expanding studies for tinnitus (e.g., building on the TiniPEA trial design).
  - Initiating modern RCTs for PEA or PEA-ALA in the prophylaxis and treatment of acute viral respiratory illnesses, including influenza and COVID-19.
  - Conducting trials for diabetic retinopathy focused on clinical endpoints.
- **Investigate Novel Sensory and Neuroinflammatory Conditions:** Explore PEA's potential in other neuroinflammatory or degenerative conditions affecting sensory systems (e.g., other forms of optic neuropathy, different types of hearing loss, or neurodegenerative diseases with sensory components), leveraging its known neuroprotective and anti-inflammatory mechanisms.
- **Optimize Delivery Systems and Combination Therapies:** Continue research into novel delivery systems (e.g., topical applications for ocular or skin conditions, intranasal for olfactory/CNS) to further enhance PEA's bioavailability and target-specific delivery. Explore and validate other synergistic combination therapies based on pathophysiological understanding.
- **Develop and Validate Biomarkers:** Invest efforts in identifying and validating biomarkers (e.g., inflammatory markers, neuroimaging changes, genetic markers)

that can predict patient response to PEA therapy or monitor treatment efficacy.

- **Long-Term Observational Studies and Registries:** Establish long-term observational studies or patient registries to gather real-world evidence on the effectiveness, safety, and optimal use patterns of PEA in chronic conditions.
- **Standardization of Research Methodologies:** Encourage the use of standardized outcome measures and definitions of clinical significance in PEA research, particularly in areas like olfactory and auditory dysfunction, to facilitate better comparison and meta-analysis of study results.

In conclusion, Palmitoylethanolamide stands as a fascinating endogenous lipid mediator with significant therapeutic potential across a spectrum of conditions, particularly those involving inflammation, immune dysregulation, and neuronal stress in sensory and respiratory systems. While the current evidence base is robust for certain applications, continued rigorous research, particularly well-powered clinical trials, is essential to fully realize its clinical utility and integrate it effectively into mainstream medical practice. Its favorable safety profile and multifaceted mechanisms of action make PEA a compelling candidate for further intensive investigation and development.

## Works cited

1. Protective and Therapeutic Efficacy of Palmitoylethanolamide in Diabetes Induced Renal Damage: A Narrative Review of Scientific Evidences, accessed June 12, 2025, <https://www.scientificarchives.com/article/protective-and-therapeutic-efficacy-of-palmitoylethanolamide-in-diabetes-induced-renal-damage-a-narrative-review-of-scientific-evidences>
2. Palmitoylethanolamide – Knowledge and References – Taylor ..., accessed June 12, 2025, [https://taylorandfrancis.com/knowledge/Medicine\\_and\\_healthcare/Physiology/Palmitoylethanolamide/](https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Physiology/Palmitoylethanolamide/)
3. Palmitoylethanolamide in the Treatment of Chronic Pain: A ..., accessed June 12, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10053226/>
4. Palmitoylethanolamide (PEA) and related amides and the cavalier King Charles spaniel, accessed June 12, 2025, <https://cavalierhealth.org/pea.htm>
5. Palmitoylethanolamide: A Natural Body-Owned Anti-Inflammatory ..., accessed June 12, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC3771453/>
6. Palmitoylethanolamide (PEA) as a Glaucoma Treatment - Vision and ..., accessed June 12, 2025, <https://www.vision-and-eye-health.com/palmitoylethanolamide-glaucoma-treatment/>
7. Palmitoylethanolamide - Wikipedia, accessed June 12, 2025, <https://en.wikipedia.org/wiki/Palmitoylethanolamide>

8. Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative ..., accessed June 12, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4667059/>
9. PALMITOYLETHANOLAMIDE (PEA): Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews - WebMD, accessed June 12, 2025, <https://www.webmd.com/vitamins/ai/ingredientmono-1596/palmitoylethanolamide-pea>
10. Therapeutic utility of palmitoylethanolamide in the treatment of ..., accessed June 12, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC3500919/>
11. Mechanisms and clinical applications of palmitoylethanolamide ..., accessed June 12, 2025, <https://pubmed.ncbi.nlm.nih.gov/39714723/>
12. A Decades-Long Journey of Palmitoylethanolamide (PEA) for Chronic Neuropathic Pain Management: A Comprehensive Narrative Review - PubMed Central, accessed June 12, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11751209/>
13. What is Palmitoylethanolamide (PEA) mechanism of action? - Consensus, accessed June 12, 2025, [https://consensus.app/search/what-is-palmitoylethanolamide-pea-mechanism-of-action/oB38O\\_CsTt6z-BX4V4rsvA/](https://consensus.app/search/what-is-palmitoylethanolamide-pea-mechanism-of-action/oB38O_CsTt6z-BX4V4rsvA/)
14. New Insights in Mast Cell Modulation by Palmitoylethanolamide - ResearchGate, accessed June 12, 2025, [https://www.researchgate.net/publication/235440008\\_New\\_Insights\\_in\\_Mast\\_Cell\\_Modulation\\_by\\_Palmitoylethanolamide](https://www.researchgate.net/publication/235440008_New_Insights_in_Mast_Cell_Modulation_by_Palmitoylethanolamide)
15. Therapeutic Use of Palmitoylethanolamide as an Anti-Inflammatory ..., accessed June 12, 2025, <https://www.mdpi.com/2673-9879/3/4/58>
16. Palmitoyl Ethanol Amide in Prophylaxis and Treatment of Viral ..., accessed June 12, 2025, <https://www.gavinpublishers.com/article/view/palmitoyl-ethanol-amide-in-prophylaxis-and-treatment-of-viral-infections>
17. Treatment of COVID-19 olfactory dysfunction with olfactory training ..., accessed June 12, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10562315/>
18. (PDF) Treatment of COVID-19 Olfactory Dysfunction with Olfactory Training, Palmitoylethanolamide with Luteolin, or Combined Therapy: A Blinded Controlled Multicenter Randomized Trial. - ResearchGate, accessed June 12, 2025, [https://www.researchgate.net/publication/371641386\\_Treatment\\_of\\_COVID-19\\_Olfactory\\_Dysfunction\\_with\\_Olfactory\\_Training\\_Palmitoylethanolamide\\_with\\_Luteolin\\_or\\_Combined\\_Therapy\\_A\\_Blinded\\_Controlled\\_Multicenter\\_Randomized\\_Trial](https://www.researchgate.net/publication/371641386_Treatment_of_COVID-19_Olfactory_Dysfunction_with_Olfactory_Training_Palmitoylethanolamide_with_Luteolin_or_Combined_Therapy_A_Blinded_Controlled_Multicenter_Randomized_Trial)
19. Effects of Palmitoylethanolamide on Aqueous Humor Outflow - PMC, accessed June 12, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4625824/>
20. Oral Ultramicronized Palmitoylethanolamide: Plasma and ... - Frontiers, accessed June 12, 2025, <https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00249/full>
21. Practical update on oral palmythopylethanolamide (PEAum) in the management of chronic pain. Narrative review - Revista de la Sociedad Española Multidisciplinar del Dolor, accessed June 12, 2025,

- <https://www.mpainjournal.com/actualizacion-practica-sobre-la-palmitoiletanolamida-peaum-oral-en-el-manejo-del-dolor-cronico-revision-narrativa1163>
22. Tinnitus and Treatment With umPEA-LUT (TiniPEA) - ClinicalTrials.Veeva, accessed June 12, 2025,  
<https://ctv.veeva.com/study/tinnitus-and-treatment-with-umpea-lut>
  23. Tinnitus and Treatment With umPEA-LUT - MedPath, accessed June 12, 2025,  
<https://trial.medpath.com/clinical-trial/b08d4c50c8517b5e>
  24. (PDF) Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin ..., accessed June 12, 2025,  
[https://www.researchgate.net/publication/362694371\\_Effect\\_of\\_Ultra-Micronized\\_Palmitoylethanolamide\\_and\\_Luteolin\\_on\\_Olfaction\\_and\\_Memory\\_in\\_Patients\\_with\\_Long\\_COVID\\_Results\\_of\\_a\\_Longitudinal\\_Study](https://www.researchgate.net/publication/362694371_Effect_of_Ultra-Micronized_Palmitoylethanolamide_and_Luteolin_on_Olfaction_and_Memory_in_Patients_with_Long_COVID_Results_of_a_Longitudinal_Study)
  25. Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study - PubMed, accessed June 12, 2025, <https://pubmed.ncbi.nlm.nih.gov/36010630/>
  26. Parosmia COVID-19 Related Treated by a Combination of Olfactory Training and Ultramicronized PEA-LUT: A Prospective Randomized Controlled Trial - ResearchGate, accessed June 12, 2025,  
[https://www.researchgate.net/publication/369830412\\_Parosmia\\_COVID-19\\_Related\\_Treated\\_by\\_a\\_Combination\\_of\\_Olfactory\\_Training\\_and\\_Ultramicronized\\_PEA-LUT\\_A\\_Prospective\\_Randomized\\_Controlled\\_Trial](https://www.researchgate.net/publication/369830412_Parosmia_COVID-19_Related_Treated_by_a_Combination_of_Olfactory_Training_and_Ultramicronized_PEA-LUT_A_Prospective_Randomized_Controlled_Trial)
  27. Palmitoylethanolamide and Luteolin for Postinfectious Olfactory Disorders: How Clinically Meaningful Is Its Effect? | ORL | Karger Publishers, accessed June 12, 2025,  
<https://karger.com/orl/article/86/3-4/118/909096/Palmitoylethanolamide-and-Luteolin-for>
  28. Palmitoylethanolamide and Luteolin for Postinfectious Olfactory Disorders: How Clinically Meaningful Is Its Effect? - PubMed, accessed June 12, 2025,  
<https://pubmed.ncbi.nlm.nih.gov/38861957/>
  29. (PDF) Targeting Neuroinflammation to Alleviate Chronic Olfactory ..., accessed June 12, 2025,  
[https://www.researchgate.net/publication/367052296\\_Targeting\\_Neuroinflammation\\_to\\_Alleviate\\_Chronic\\_Olfactory\\_Dysfunction\\_in\\_Long\\_COVID\\_A\\_Role\\_for\\_Investigating\\_Disease-Modifying\\_Therapy\\_DMT](https://www.researchgate.net/publication/367052296_Targeting_Neuroinflammation_to_Alleviate_Chronic_Olfactory_Dysfunction_in_Long_COVID_A_Role_for_Investigating_Disease-Modifying_Therapy_DMT)
  30. A Combination of  $\alpha$ -Lipoic Acid (ALA) and Palmitoylethanolamide ..., accessed June 12, 2025,  
<https://www.tandfonline.com/doi/pdf/10.1080/19390211.2021.1966152>
  31. Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy - PubMed Central, accessed June 12, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11434759/>
  32. Endocannabinoids in aqueous humour of patients with or without diabetes, accessed June 12, 2025, <https://bmjophth.bmj.com/content/5/1/e000425>
  33. Nature Communications Medicine Publishes Positive, Real World Data for Tinnitus Patients Treated with Unique, FDA Approved Stimulation Device - BioSpace,



accessed June 12, 2025,

<https://www.biospace.com/press-releases/nature-communications-medicine-publishes-positive-real-world-data-for-tinnitus-patients-treated-with-unique-fda-approved-stimulation-device>

34. Real-World Study Reports 91% of Tinnitus Patients Improved With Neuromod's FDA-Approved Device - BiopharmaTrend, accessed June 12, 2025, <https://www.biopharmatrend.com/post/1264-real-world-study-reports-91-of-tinnitus-patients-improved-with-neuromods-fda-approved-device/>
35. Novel Targeted Therapy Under Study in Selected Patients With Advanced Solid Tumors, accessed June 12, 2025, <https://ascopost.com/news/april-2025/novel-targeted-therapy-under-study-in-selected-patients-with-advanced-solid-tumors/>
36. Aptose Provides Clinical Update for the Tuspentinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial, accessed June 12, 2025, <https://www.aptose.com/news-media/press-releases/detail/317/aptose-provides-clinical-update-for-the-tuspentinib-based>
37. 11 Foods That May Help Support Your Hearing Health - AARP, accessed June 12, 2025, <https://www.aarp.org/health/conditions-treatments/foods-vitamins-that-support-hearing-health/>
38. Assessment of COVID-19-related olfactory dysfunction and its association with psychological, neuropsychiatric, and cognitive symptoms - Frontiers, accessed June 12, 2025, <https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2023.1165329/full>